8-K: AbbVie Lowers 2024 Earnings Guidance Due to $937 Million IPR&D Expense

AbbVie has revised its 2024 earnings guidance downward due to a significant $937 million expense related to acquired IPR&D and milestones in the second quarter.

Summary

• AbbVie has announced that its second quarter 2024 results will include a $937 million pre-tax expense for acquired IPR&D and milestones.
• This expense will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.52.
• The company's full-year 2024 adjusted diluted earnings per share guidance has been revised to a range of $10.61 to $10.81, which includes the impact of the second quarter IPR&D expense.
• The second quarter 2024 adjusted diluted earnings per share guidance is now $2.53 to $2.57, also reflecting the IPR&D expense.
• AbbVie does not forecast future IPR&D expenses due to the uncertainty of these transactions.

Sentiment

Score: 3

Explanation: The document conveys negative sentiment due to the significant reduction in earnings guidance caused by the large IPR&D expense. The lack of predictability for future IPR&D expenses also adds to the uncertainty.

Negatives

• The $937 million IPR&D expense significantly reduces the company's earnings per share.
• The full-year and second quarter earnings guidance has been lowered to reflect the impact of the IPR&D expense.

Risks

• The company's inability to forecast future IPR&D expenses creates uncertainty in future earnings.
• The actual results for the second quarter may differ from these preliminary estimates.
• The company faces risks related to intellectual property, competition, research and development, litigation, and regulatory changes.

Future Outlook

AbbVie's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.

Management Comments

• AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.
• The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024.

Industry Context

The pharmaceutical industry often sees fluctuations in earnings due to R&D expenses and acquisitions, making AbbVie's situation not entirely unique, but the size of the IPR&D expense is significant.

Comparison to Industry Standards

• Other large pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson also experience fluctuations in earnings due to IPR&D expenses.
• However, the $937 million expense for AbbVie in a single quarter is a substantial amount, potentially indicating a significant acquisition or licensing deal.
• Compared to previous quarters, this IPR&D expense is notably higher, suggesting a deviation from typical operational costs.

Stakeholder Impact

• Shareholders will likely react negatively to the reduced earnings guidance.
• Analysts will likely revise their earnings estimates for AbbVie.
• The company's credit rating could be affected by the increased expenses.

Key Dates

Keywords

IPR&D, milestones, earnings per share, EPS, financial guidance, AbbVie, pharmaceuticals, acquisitions